Autopsy report · NCT00459641

Safety and Tolerability of I-040302 in Children and Young Adults With Solitary Bone Cysts

“Stopped before any site initiation or any recruitment due to change in overall product development plan”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Kuros Biosurgery AG

Sponsor type

Industry

Conditions

Bone Cysts

Interventions

I-040302; Standard of Care

Participants

0

Trials that died the same way

• A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
  “The development was stopped due to company's strategy consideration” (68% match in meaning)
• Clinical Evaluation of Systane® Balance in Dry Eye Subjects
  “Discontinuation of product development” (64% match in meaning)
• Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects
  “Product development halted for business reasons.” (64% match in meaning)
• A Clinical Investigation to Assess the Effectiveness of Benzocaine Condoms in Healthy Adult Men
  “Change of the product development strategy” (62% match in meaning)
• A Study to Test if TEV-53275 is Effective in Relieving Asthma
  “Stopped for strategic reasons” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.